Steven Powell, MD, Lab
Primary Research Focus
Dr. Powell Bio
Steven Powell, MD, is a practicing medical oncologist and a physician scientist. His laboratory focuses on integrating novel immunotherapies into the management of head and neck cancer and concurrently developing predictive biomarkers. His primary goal is to comprehend how to best incorporate immunotherapy into the management of locally advanced and metastatic head and neck cancer.
Dr. Powell’s research has led to novel strategies to use immune checkpoint inhibitors in combination with chemotherapy and radiation to augment anti-tumor response. Additionally, his work has evaluated biomarkers of immune response. As a clinician, Dr. Powell seeks to bring what he finds in the lab to clinical trials, to directly impact patient care.
- Associate scientist in the Cancer Biology Research Center
- Assistant Professor at the University of South Dakota Sanford School of Medicine, Department of Surgery
- Bachelor’s of Science and Engineering in Biomedical Engineering from Arizona State University (Tempe, AZ)
- Doctor of Medicine from the University of South Dakota Sanford School of Medicine, Vermillion, SD
- Residency in Internal Medicine at the University of Minnesota (Minneapolis, MN)
- Fellowship in Hematology and Oncology at the University of Minnesota (Minneapolis, MN)
Behind the research
Translational Research Laoratory
The host immune response is critical for the clearance of head and neck cancer during chemoradiotherapy (CRT). Dr. Powell’s translational research laboratory focuses on evaluation of human biospecimens to evaluate targets for novel therapies to augment this response during CRT. Additionally, his lab evaluates immune biomarkers in this setting. We are currently evaluating the peripheral blood immunocyte response during standard CRT and during investigational immunotherapy combination CRT clinical studies. Patient immune phenotype and functional response during treatment is assessed to determine peripheral blood immune response. Additionally, we are investigating tumor and tumor microenvironment factors that may impact the host immune response. In collaboration with the Spanos and Vermeer labs, Dr. Powell’s lab utilizes an immune competent mouse model that harbors HPV+ tumors to explore novel immuno-oncology agents in combination with CRT. The primary goal of his lab is to develop a biomarker driven approach to include novel therapeutics into the management of advanced head and neck cancer.
Dr. Powell is a principal investigator for head and neck cancer, lung cancer, melanoma, and genomic oncology trials at Sanford Health. His investigator-initiated research has an emphasis on integrating novel immunotherapies into the management of head and neck cancers. Access current active clinical trials here.
Contact Christie Ellison or Janet Wernisch for more information on Dr. Powell’s investigator-initiated studies.
|Powell Lab in the Press
September 16, 2016: NIH Selects Sanford for grant to move cancer research to clinical trials
July 26, 2016: Genetic profiling increases cancer treatment option, Sanford Study Finds
July 19, 2016: Sanford physician assists in developing new treatment to prevent nausea, vomiting caused by chemotherapy
February 24, 2016: Sanford head, neck cancer clinical trial will aim to activate immune system
April 2, 2015: Sanford enrolling patients for head, neck cancel clinical trial
August 1, 2014: Sanford clinical trial looks for genetic targets in cancer